Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and SABR in Locally Advanced Pancreatic Adenocarcinoma
NCT03245541Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2020
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03245541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245541.